Skip to main content
Menu

AlphaLISA SureFire Ultra High Performance Human and Mouse Phospho-STAT3 (Tyr705) Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ High Performance Human and Mouse Phospho-STAT3 (Tyr705) assay is a sandwich immunoassay for quantitative detection of phospho-STAT3 (Tyr705) in cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 10 µL

The AlphaLISA™ SureFire® Ultra™ High Performance Human and Mouse Phospho-STAT3 (Tyr705) assay is a sandwich immunoassay for quantitative detection of phospho-STAT3 (Tyr705) in cellular lysates using Alpha Technology.

Product variants
Unit Size: 100 Assay Points
Part #:
ALSU-PST3-B-HV
List price
USD 722.00
Your online price:
Unit Size: 500 Assay Points
Part #:
ALSU-PST3-B500
List price
USD 2,441.00
Your online price:
Unit Size: 10,000 Assay Points
Part #:
ALSU-PST3-B10K
List price
USD 14,688.00
Your online price:
Unit Size: 50,000 Assay Points
Part #:
ALSU-PST3-B50K
List price
USD 46,690.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Overview

Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor that mediates cellular responses to cytokines and growth factors, regulating genes involved in proliferation, survival, and immune responses. STAT3 is activated by phosphorylation at Tyr705, leading to dimerization, nuclear translocation, and DNA binding. STAT3 regulates expression of genes including c-MYC, cyclin D1, BCL-XL, and VEGF, promoting cell cycle progression and survival. Constitutive STAT3 activation is found in approximately 70% of tumors, where it drives oncogenesis and creates an immunosuppressive microenvironment. STAT3 inhibitors are being developed as cancer therapeutics to target tumor cells and restore anti-tumor immunity.

The AlphaLISA SureFire Ultra High Performance Human and Mouse Phospho-STAT3 (Tyr705) is a sandwich immunoassay for the quantitative detection of phospho-STAT3 (Tyr705) in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

How it works

Phospho-AlphaLISA SureFire Ultra assay principle

The Phospho-AlphaLISA SureFire Ultra assay measures a protein target when phosphorylated at a specific residue.

The assay uses two antibodies which recognize the phospho epitope and a distal epitope on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of phosphoprotein present in the sample.

assay principle Phospho AlphaLISA Surefire Ultra

 

Phospho-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Phospho-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2 plates assay protocol alphalisa surefire ultra phospho assay

Phospho-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Phosphorylated target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1 plate assay protocol alphalisa surefire ultra phospho assay

Assay validation

Induction of STAT3 (Tyr705) phosphorylation in THP-1 derived macrophages

THP-1 cells were seeded in a 96-well plate (50,000 cells/well) in complete medium containing 100 nM PMA and incubated for 24 hours at 37°C, 5% CO2. The THP-1 derived macrophages were starved in HBSS + 0.1% BSA for 2 hours and then stimulated with increasing concentrations of either IFNα or IL-6 for 20 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 5,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IFNα and IL-6 treatment resulted in a dose dependent increase in STAT3 (Tyr705) phosphorylation, while STAT3 Total levels remained unchanged.

STAT3 Phospho (HP) assay validation - Activator
STAT3 Phospho (HP) assay validation - Activator

 

Induction of STAT3 phosphorylation in various cell models

HeLa and A549 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. Cells were starved for 20 hours and then stimulated with increasing concentrations of IFNα for 30 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IFNα treatment resulted in a dose dependent increase in STAT3 (Tyr705) phosphorylation, while STAT3 Total levels remained unchanged.

STAT3 Phospho (HP) assay validation - Activator

 

STAT3 Phospho (HP) assay validation - Activator

A549 and HeLa cells were seeded in a 96-well plate (20,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. Cells were starved for 20 hours and then stimulated with increasing concentrations of IL-6 for 15 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IL-6 treatment resulted in a dose dependent increase in STAT3 (Tyr705) phosphorylation, while STAT3 Total levels remained unchanged.

STAT3 Phospho (HP) assay validation - Activator

 

STAT3 Phospho (HP) assay validation - Activator

RAW 264.7 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. Cells were starved for 2 hours and then stimulated with increasing concentrations of IFNγ (mouse) for 20 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IFNγ treatment resulted in a dose dependent increase in STAT3 (Tyr705) phosphorylation, while Total levels remained unchanged.

STAT3 Phospho (HP) assay validation - Activator

Inhibition of STAT3 (Tyr705) phosphorylation in THP-1 derived macrophages

THP-1 cells were seeded in a 96-well plate (50,000 cells/well) in complete medium containing 100 nM PMA and incubated for 24 hours at 37°C, 5% CO2. The THP-1 derived macrophages were treated with increasing concentrations of Ruxolitinib for 2 hours and then stimulated with 10 ng/mL IFNγ for 20 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 5,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, treatment with Ruxolitinib resulted in a dose-dependent decrease in the levels of Phospho STAT3 (Tyr705), while Total levels remained unchanged.

STAT3 Phospho (HP) assay validation - Inhibitor

Assay sensitivity

STAT3 p-Y705 High Performance assay sensitivity

THP-1 cells were seeded in a 96-well plate (50,000 cells/well) in complete medium containing 100 nM PMA and incubated for 24 hours at 37°C, 5% CO2. The THP-1 derived macrophages were starved in HBSS + 0.1% BSA for 2 hours and then stimulated with increasing concentrations of IFNα for 20 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra STAT3 assays. For the detection step, 10 µL of cell lysate (approximately 5,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

STAT3 assay comparisons

Cell lysate was prepared from A431 cells cultured to confluency in a T175 flask, treated with 2 µg/mL EGF for 10 minutes and lysed in 10 mL of Lysis Buffer for 10 minutes at RT with shaking.

Lysate was serially diluted in Lysis Buffer and STAT3 Phospho (Tyr705) and Total levels were evaluated using respective AlphaLISA SureFire Ultra High Performance STAT3 assays. For the detection step, 10 µL of cell lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Approximate number of cells is indicated. The dotted line represents assay background. The STAT3 High Performance assays have a broad dynamic range and can detect STAT3 expression in less than 50 cells/datapoint.

STAT3 pY705 High Performance assay sensitivity – Positive control lysate dilution

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Product Group
Kit
Protocol Time
2h at RT
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
STAT3
Target Class
Phosphoproteins
Target Species
Human
Mouse
Technology
Alpha
Therapeutic Area
Inflammation
Neuroscience
Oncology
Unit Size
500 Assay Points

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Guide Icon
Guide
AlphaLISA SureFire Ultra: the ultimate guide for successful experiments

The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay

Several biological processes are regulated by...

Loading...

Scroll Icon

Revvity AI Assistant Beta